Japan’s PMDA Expands Registration Support for Foreign Drug and Medical Device Companies

Leave a comment

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) is strengthening its role as a global regulator by offering more and more registration support for foreign pharmaceutical and medical device manufacturers. The PMDA has established overseas offices, accelerated pathways for product approval, developed harmonized regulatory frameworks, and created structured consultation programs. By establishing these programs, PMDA is positioning Japan as both a strategic launch market for new products and a gateway for companies looking to gain regulatory approval throughout Asia.

Going Global with International Offices

Headquartered in Tokyo, the PMDA has established regional offices in Osaka and Toyama. In addition to their U.S. office in Washington, D.C., the PMDA established an Asian office in Bangkok in mid-2024. In the United States, the PMDA Washington D.C. office intends to work closely with the US FDA to provide individualized support for U.S manufacturers and developers of innovative products interested in the Japanese market.

Fast Review Timelines and Early Access Pathways

According to international studies that benchmark various drug regulatory agencies, Japan typically ranks among major regulatory authorities with one of the fastest approval times for new drugs. The PMDA has established many pathways to help expedite the approval process and get patients access to new drugs and medical devices as quickly as possible:

  • Priority Review: available for innovative products that treat serious diseases
  • SAKIGAKE (Forerunner) Designation: offers concierge-style regulatory support, expedited scientific advice, and a target six-month review period
  • Conditional Early Approval: allows earlier market entry based on limited but promising clinical data

These programs should be of particular interest to foreign companies willing to submit their product application in Japan first or in parallel with other major developed markets.

Orphan and Rare Disease Programs

The PMDA is committed to providing ongoing support for innovative treatments for rare diseases. New drugs that treat rare diseases can be granted orphan drug status. With this status, the applicant will receive incentives such as priority consultation, priority review, premium pricing, R&D grants, and extended time before requiring re-examination of the drug. It is important to note that foreign companies will qualify for all or most of these incentives if they demonstrate a realistic drug development plan and have established some form of a local presence to support their development activities within Japan. Several world-first approvals in oncology and rare diseases have already been granted in Japan under this framework.

Japan as a Regulatory Gateway to Asia

Beyond the domestic market, PMDA plays a growing role in regional regulatory reliance. Several Asian regulatory authorities have designated Japan as the primary source of reference for their local markets. For example, having drug approval from the PMDA will exempt applicants from conducting Phase III trials in India and enable them to go through an abbreviated review in Taiwan, Malaysia, Indonesia, the Philippines, and Thailand. For foreign companies, a Japanese approval can therefore accelerate access to other Asian markets.

Harmonized Regulations and Flexible Clinical Development

Through its leadership roles within international frameworks such as ICH, ICMRA, MDSAP, and APEC regulatory initiatives, the PMDA has taken significant steps towards aligning regulatory standards with international norms throughout the clinical development lifecycle. For example, in December 2023, the PMDA issued a notification indicating that, as long as there is sufficient safety and tolerability data for Japanese patients from existing clinical studies, there is generally no need for an additional Phase 1 study in Japan. PMDA’s policy changes create a more streamlined approach for foreign companies wanting to conduct multi-regional clinical trials (MRCTs) including Japan and support Japan’s involvement in the early phases of MRCTs. Furthermore, the PMDA has continued to expand its acceptance of using real-world data (RWD) and real-world evidence (RWE) in disease areas that have high unmet medical needs.

PMDA Consultation Sessions for Foreign Companies

A cornerstone of PMDA’s expanded support is its consultation ecosystem, which spans early research through proof-of-concept clinical development. Through Regulatory Science (RS) General Consultations and RS Strategy Consultations, companies can obtain tailored scientific and regulatory advice from PMDA experts and reviewers.

These consultations are especially popular among venture companies, start-ups, and academic spinouts, and can be conducted online or face-to-face. Early-stage consultations are often free of charge, lowering the barrier for foreign innovators unfamiliar with Japan’s regulatory environment.

MEDISO and Clinical Research Infrastructure Support

Complementing PMDA’s regulatory role, the Medical Innovation Support Office (MEDISO) provides free consultations to foreign companies on regulatory requirements, licensing, approval pathways, and commercialization strategies. MEDISO specifically targets companies that introduce their products to Japan for the first time.

In addition, Japan’s network of Clinical Research Core Hospitals offers operational support for clinical trial planning, execution, and data management. These institutions have extensive experience working with not only the PMDA and foreign sponsors, particularly in oncology, rare diseases, and regenerative medicine.

Market Access Advantages Under Universal Health Coverage

Japan’s universal health coverage system further enhances its attractiveness as a launch market. All Japanese citizens are publicly insured, which means reimbursement is just as important as registration for all medical products. New drugs are typically listed in the National Health Insurance (NHI) Drug Price Standard within 90 days of product approval. Notably, for existing therapies approved already in Japan, there are no formal health technology assessment (HTA) requirements before listing.

Compared with HTA-driven systems in other regions of the world, this framework enables faster and more predictable patient access. According to research by Pharmaceutical Research and Manufacturers of America (PhRMA), the time from approval to reimbursement in Canada and France is significantly higher than in Japan (over 20 months vs. less than 3 months).

Conclusion

Through faster reviews, overseas offices, regulatory harmonization, and dedicated support programs, the PMDA has actively lowered barriers for foreign pharmaceutical and medical device manufacturers. For foreign manufacturers willing to engage early and strategically, PMDA’s evolving support framework offers both regulatory efficiency and long-term commercial advantages.

Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.